(Reuters) – Johnson & Johnson (JNJ.N) aims to test its experimental coronavirus vaccine in up to 60,000 volunteers in a late-stage trial scheduled to start in September, according to a U.S. government database of clinical trials.

The trial would be conducted in nearly 180 sites across the United States and other countries including Brazil and Mexico, according to the information posted on clinicaltrials.gov on Aug. 10.

Rival coronavirus vaccine makers such as Moderna Inc (MRNA.O) and Pfizer (PFE.N) are targeting recruitment of up to 30,000 volunteers for their late-stage studies.

J&J did not immediately respond to Reuters request for comment.

Shares of the company rose marginally on Thursday, paring their earlier losses, after the Wall Street Journal first reported the trial size.

FILE PHOTO: The company logo for Johnson & Johnson is displayed on a screen to celebrate the 75th anniversary of the company’s listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid

Reuters last week reported that the Trump administration’s coronavirus vaccine project was recruiting scientists in South Africa and Latin America to help test possible vaccines in U.S.- backed clinical trials.


Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli

Reuters source: